IDEAYA Biosciences Reports Q3 2026 Loss of $125.7 Million
IDEAYA reported $10.2 million in revenue, primarily from services under its darovasertib license agreement with Servier, and ended the quarter with approximately $1.15 billion in cash, cash equivalents and marketable securities. It reaffirmed its cash runway guidance into 2030.
IDEAYA Biosciences, Inc. announced its financial results for the third quarter of 2026, reporting a net loss of $125.7 million and revenue of $10.2 million, the latter primarily driven by services under its darovasertib license agreement with Servier. The company ended the quarter with approximately $1.15 billion in cash, cash equivalents, and marketable securities, and reaffirmed its cash runway guidance into 2030. Key operational updates included the completion of the NDA submission for darovasertib in metastatic uveal melanoma during the third quarter and the presentation of updated clinical data for IDE849 at ESMO 2026.
The company also announced an R&D Day scheduled for November 16, 2026, to discuss preclinical data for its MTAP/CDKN2A-deficient cancer programs.